Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 21,516 matching trials from the live ClinicalTrials.gov search.

Filters: Boston, Massachusetts Clear all

Conditions: Mother-child Relations, Parenting, Parent Child Abuse, Family Conflict, Parental Stress, Family Relations, Childhood Disorder of Social Functioning, Unspecified
Interventions: Therapeutic intervention; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions: Xylitol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anxiety Disorders, Mental Disorder, Psychiatric Disorder
Interventions: Transcranial magnetic stimulation, Sham transcranial magnetic stimulation; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Interventions: Codrituzumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Interventions: Experimental; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 40
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 33 more

Conditions: Depression
Interventions: Escitalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Real Acupressure Band, Placebo Acupressure Band; Procedure
Lead sponsor: University of South Florida; Other
Eligibility: 4 Years to 18 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 24
States / cities: Long Beach, California • Los Angeles, California • Hartford, Connecticut + 20 more

Conditions: Diabetes Mellitus, Hyperglycemia
Interventions: Closed-loop blood glucose control; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions: AP-SA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more

Conditions: Major Depressive Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Parkinson's Disease
Interventions: Inosine, Placebo; Drug
Lead sponsor: Michael Alan Schwarzschild; Other
Eligibility: 30 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more

Conditions: Hereditary Angioedema
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 39
States / cities: Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more

Conditions: Sjogren Syndrome
Interventions: VAY736, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 23
States / cities: Fullerton, California • La Palma, California • Brandon, Florida + 19 more

Conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma
Interventions: Binimetinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more

Conditions: Breast Cancer
Interventions: docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 62
States / cities: Little Rock, Arkansas • La Jolla, California • Montebello, California + 55 more

Conditions: Posttraumatic Stress Disorder, Tobacco Dependence
Interventions: Tobacco treatment, Health Education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Acute Alcoholic Hepatitis
Interventions: ELAD, Standard of Care treatment; Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 21
States / cities: Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 16 more

Conditions: Pre-term Birth
Interventions: Not listed
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 1,210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 16
States / cities: Birmingham, Alabama • San Diego, California • Newark, Delaware + 13 more

Conditions: Diagnostic Errors
Interventions: ADEPT Program; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 7,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Hepatitis C
Interventions: SOF/VEL/VOX, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Hodgkin Lymphoma
Interventions: brentuximab vedotin, nivolumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 13
States / cities: Duarte, California • Stanford, California • Boston, Massachusetts + 10 more

Conditions: Reproductive Disorder
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Childhood Cancer Survivors
Interventions: Health Insurance Navigation Tools Program; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Depression
Interventions: Medtronic Percept RC System, One Month Blinded Discontinuation Period; Device · Behavioral
Lead sponsor: Wayne Goodman MD; Other
Eligibility: 22 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Boston, Massachusetts • Houston, Texas • Seattle, Washington

Search by objective public record fields.

Project BELONG: Breaking the Cycle of Intergenerational Family Violence and Trauma

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease

Connectomic Targeted TMS Target for Refractory Anxiety

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

TECTONIC CAD IVL IDE Study

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy

Inpatient Closed-loop Glucose Control

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

Study of Urate Elevation in Parkinson's Disease, Phase 3

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Tobacco Treatment as Augmentation for Cognitive Processing Therapy for PTSD

To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

fFN Clinical Evaluation in Asymptomatic Women at High Risk for Preterm Birth

Achieving Diagnostic Excellence Through Prevention and Teamwork

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Recall by Genotype: Neuropeptide Stimulation

Virtual Health Insurance Navigation Pilot Program for Childhood Survivors (HINTII)

Deep Brain Stimulation of Treatment-Resistant Bipolar Depression